Vitae Pharmaceuticals, Inc. (Nasdaq: VTAE)


The firm is investigating potential claims against the board of directors of Vitae Pharmaceuticals, Inc. ("Vitae" or the "Company") (VTAE) concerning the proposed acquisition of the Company by Allergan plc ("Allergan").

Under the terms of the offer, Allergan would acquire Vitae in a transaction valued at approximately $640 million. Pursuant to the deal, Vitae stockholders will receive $21.00 in cash per share of Vitae owned.

Our investigation concerns whether the Vitae board of directors is fulfilling its fiduciary duties, maximizing the value of the Company, disclosing all material benefits and costs, and obtaining full and fair consideration for Company stockholders.

If you are a current shareholder and would like to discuss your options of exercising your rights as a shareholder, which include ensuring that the company is getting the highest possible price for the company, and that the board of directors will act in the best interest of the shareholders, please contact us.

Please submit the following information so we can determine if you qualify for the suit. If you don't know all the specific details, partial information is also acceptable.

Personal Information
Name:
Phone #:
E-mail Address:
Stock Information
Do you currently own the stock? Yes   No
Purchase Date:
Quantity Purchased:
Purchase Price Per Share:

Please Note: Neither the submission to nor the receipt of information by The Law Offices of Marc S. Henzel or one of its attorneys through this website constitutes an agreement by the firm to represent the individual and does not create an attorney-client relationship.